Tissue | Expression Dynamics | Abbreviation |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | | BPH: Benign Prostatic Hyperplasia |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000717819 | Thyroid | PTC | transmembrane receptor protein serine/threonine kinase signaling pathway | 156/5968 | 355/18723 | 1.02e-06 | 1.51e-05 | 156 |
GO:0002262113 | Thyroid | PTC | myeloid cell homeostasis | 79/5968 | 157/18723 | 1.11e-06 | 1.64e-05 | 79 |
GO:000703010 | Thyroid | PTC | Golgi organization | 79/5968 | 157/18723 | 1.11e-06 | 1.64e-05 | 79 |
GO:001810717 | Thyroid | PTC | peptidyl-threonine phosphorylation | 62/5968 | 116/18723 | 1.16e-06 | 1.69e-05 | 62 |
GO:0070849111 | Thyroid | PTC | response to epidermal growth factor | 32/5968 | 49/18723 | 1.56e-06 | 2.19e-05 | 32 |
GO:007030116 | Thyroid | PTC | cellular response to hydrogen peroxide | 54/5968 | 98/18723 | 1.62e-06 | 2.27e-05 | 54 |
GO:00457867 | Thyroid | PTC | negative regulation of cell cycle | 166/5968 | 385/18723 | 1.93e-06 | 2.64e-05 | 166 |
GO:000756917 | Thyroid | PTC | cell aging | 68/5968 | 132/18723 | 2.09e-06 | 2.84e-05 | 68 |
GO:0030218113 | Thyroid | PTC | erythrocyte differentiation | 63/5968 | 120/18723 | 2.14e-06 | 2.89e-05 | 63 |
GO:000110119 | Thyroid | PTC | response to acid chemical | 69/5968 | 135/18723 | 2.55e-06 | 3.34e-05 | 69 |
GO:19019878 | Thyroid | PTC | regulation of cell cycle phase transition | 167/5968 | 390/18723 | 2.97e-06 | 3.87e-05 | 167 |
GO:0010833111 | Thyroid | PTC | telomere maintenance via telomere lengthening | 46/5968 | 81/18723 | 3.10e-06 | 4.04e-05 | 46 |
GO:0031098111 | Thyroid | PTC | stress-activated protein kinase signaling cascade | 113/5968 | 247/18723 | 3.16e-06 | 4.10e-05 | 113 |
GO:0006278110 | Thyroid | PTC | RNA-dependent DNA biosynthetic process | 43/5968 | 75/18723 | 4.61e-06 | 5.66e-05 | 43 |
GO:003221010 | Thyroid | PTC | regulation of telomere maintenance via telomerase | 33/5968 | 53/18723 | 5.10e-06 | 6.20e-05 | 33 |
GO:000675325 | Thyroid | PTC | nucleoside phosphate metabolic process | 205/5968 | 497/18723 | 5.24e-06 | 6.35e-05 | 205 |
GO:000911725 | Thyroid | PTC | nucleotide metabolic process | 202/5968 | 489/18723 | 5.46e-06 | 6.60e-05 | 202 |
GO:001931810 | Thyroid | PTC | hexose metabolic process | 108/5968 | 237/18723 | 6.42e-06 | 7.65e-05 | 108 |
GO:0048511111 | Thyroid | PTC | rhythmic process | 131/5968 | 298/18723 | 7.06e-06 | 8.33e-05 | 131 |
GO:00346447 | Thyroid | PTC | cellular response to UV | 49/5968 | 90/18723 | 7.58e-06 | 8.77e-05 | 49 |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
MAPK1 | CD8TEXINT | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.57e-01 | |
MAPK1 | CD8TEREX | Colorectum | AD | ITGA1,YPEL1,UBASH3B, etc. | 2.43e-01 | |
MAPK1 | MAIT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.38e-01 | |
MAPK1 | CD8TEREX | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.84e-01 | |
MAPK1 | CD8TEXINT | Colorectum | ADJ | ITGA1,YPEL1,UBASH3B, etc. | 1.00e-01 | |
MAPK1 | CD8TEREX | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 6.38e-02 | |
MAPK1 | TREG | Colorectum | CRC | ITGA1,YPEL1,UBASH3B, etc. | 1.20e-01 | |
MAPK1 | TH17 | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 8.39e-02 | |
MAPK1 | CD8TEREX | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 2.37e-01 | |
MAPK1 | MAIT | Colorectum | FAP | ITGA1,YPEL1,UBASH3B, etc. | 1.13e-01 | |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK1 | SNV | Missense_Mutation | | c.241G>A | p.Glu81Lys | p.E81K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-BH-A0B5-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
MAPK1 | SNV | Missense_Mutation | rs747124623 | c.994G>A | p.Asp332Asn | p.D332N | P28482 | protein_coding | deleterious(0.03) | benign(0.001) | TCGA-E2-A14N-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
MAPK1 | insertion | Frame_Shift_Ins | novel | c.1024_1025insTTGTGAGCCAAGGTAGAAGCAGTTGCTGGGGAGATGC | p.Lys342IlefsTer20 | p.K342Ifs*20 | P28482 | protein_coding | | | TCGA-AN-A03Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1BI-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD |
MAPK1 | SNV | Missense_Mutation | | c.961G>A | p.Asp321Asn | p.D321N | P28482 | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-DG-A2KL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-DS-A0VN-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD |
MAPK1 | SNV | Missense_Mutation | | c.964N>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A1QS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.404G>A | p.Arg135Lys | p.R135K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-EA-A3HT-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
MAPK1 | SNV | Missense_Mutation | | c.964G>A | p.Glu322Lys | p.E322K | P28482 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-EA-A5ZD-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | PROGESTERONE | PROGESTERONE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | SPINASAPONIN A METHYL ESTER | SPINASAPONIN A METHYL ESTER | 20951582 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | DIHYDROGAMBOGIC ACID | DIHYDROGAMBOGIC ACID | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | TREQUINSIN HYDROCHLORIDE | TREQUINSIN HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | BENZOTHIAZOL-2-YLAMINE | CHEMBL329785 | 22982122 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | PHENETHYLISOTHIOCYANATE | PHENETHYLISOTHIOCYANATE | 22607231 |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | GENTIAN VIOLET | GENTIAN VIOLET | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | MITOXANTRONE DIHYDROCHLORIDE | MITOXANTRONE HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | DAUNORUBICIN HYDROCHLORIDE | DAUNORUBICIN HYDROCHLORIDE | |
5594 | MAPK1 | SERINE THREONINE KINASE, ENZYME, CLINICALLY ACTIONABLE, KINASE, DRUGGABLE GENOME, DRUG RESISTANCE, TRANSCRIPTION FACTOR | | ZM-449829 | CHEMBL154580 | |